Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy reaffirmed a Buy rating on Gain Therapeutics with an unchanged $7 price target, citing clinical momentum for GT-02287 in Parkinson's disease and its differentiated GCase strategy. The FDA clearance of the IND for a phase 2 study and upcoming data support this view. Roth MKM also maintained a Buy rating with an $8 target. Despite recent analyst optimism, GANX stock has dropped 38.2% over six months.
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Gain Therapeutics. The associated price target remains the same with $7.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Jason McCarthy has given his Buy rating due to a combination of factors, including clinical momentum and a favorable competitive landscape for GT-02287 in Parkinson’s disease. The recent FDA clearance of the IND for a phase 2 PD study, along with upcoming nine‑month phase 1b data, supports continued development and underpins his confidence in Gain Therapeutics’ lead program.
He also views the failure of Bial’s GCase activator in phase 2 as reinforcing the differentiated potential of Gain’s GCase‑targeting chaperone approach. Because GT-02287 may exert broader cellular effects through protein folding and trafficking, and compares favorably to other GCase modulators such as Vanqua Bio’s VQ-101, McCarthy sees enhanced partnering prospects and long‑term value creation, justifying his unchanged $7 price target and Buy rating.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $8.00 price target.
GANX’s price has also changed moderately for the past six months – from $3.220 to $1.990, which is a -38.20% drop .